(1) Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening.(2) Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening. (3) Patients who are not expected to survive longer than 24 hours after commencement of study drug administration.(4) Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO).(5) Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use.(6) Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis).(7)Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19.(8) Patients who have a disease including leukemia and leukocytosis that causes leukocytosis.(9) Patients who have a chronic kidney disease requiring dialysis.(10) Patients who have severe liver failure (Child Pugh grade C).(11) Patients aged 80 years or older with any of heart failure, cerebrovascular disease, obesity (BMI 30 or higher), dyslipidemia, hypertension or diabetes.

(1) Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening.(2) Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening. (3) Patients who are not expected to survive longer than 24 hours after commencement of study drug administration.(4) Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO).(5) Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use.(6) Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis).(7)Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19.(8) Patients who have a disease including leukemia and leukocytosis that causes leukocytosis.(9) Patients who have a chronic kidney disease requiring dialysis.(10) Patients who have severe liver failure (Child Pugh grade C).(11) Patients aged 80 years or older with any of heart failure, cerebrovascular disease, obesity (BMI 30 or higher), dyslipidemia, hypertension or diabetes.

(1) Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening.(2) Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening. (3) Patients who are not expected to survive longer than 24 hours after commencement of study drug administration.(4) Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO).(5) Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use.(6) Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis).(7)Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19.(8) Patients who have a disease including leukemia and leukocytosis that causes leukocytosis.(9) Patients who have a chronic kidney disease requiring dialysis.(10) Patients who have severe liver failure (Child Pugh grade C).

(1) Patients who have been participating in other intervention studies, such as studies on unapproved pharmacotherapy, within 90 days prior to screening.(2) Patients who have experienced off-label use of approved drugs (including those for COVID-19 treatment other than steroids as standard treatment) within 7 days prior to screening. (3) Patients who are not expected to survive longer than 24 hours after commencement of study drug administration.(4) Patients who are using invasive ventilator or extracorporeal membrane oxygenation (ECMO).(5) Patients who have a chronic respiratory disease requiring continuous home oxygen therapy or ventilator use.(6) Patients with an underlying condition that is considered very unlikely to withdraw ventilator (e.g., motor neuron disease, Duchenne muscular dystrophy, rapidly progressive interstitial pulmonary fibrosis).(7)Patients who have a disease including bronchial asthma, lower respiratory tract infections, and interstitial lung diseases that may affect the assessment of the clinical study, since before the symptom onset of COVID-19.(8) Patients who have a disease including leukemia and leukocytosis that causes leukocytosis.(9) Patients who have a chronic kidney disease requiring dialysis.(10) Patients who have severe liver failure (Child Pugh grade C).